StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$37.04−0.52 (-1.38%)

Close on Nov 20, 2026Market cap $3.59BP/E –Yield –

Xenon Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Xenon Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$338.53M. For fiscal 2025 it was -$279.92M. The highest annual figure on record is $45.05M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$279.92M–
FY2024Dec 31, 2024-$184.46M–
FY2023Dec 31, 2023-$156.73M–
FY2022Dec 31, 2022-$103.92M–
FY2021Dec 31, 2021-$71.55M–
FY2020Dec 31, 2020-$50.76M–
FY2019Dec 31, 2019-$5.95M–
FY2018Dec 31, 2018-$35.23M–
FY2017Dec 31, 2017-$29.04M–
FY2016Dec 31, 2016-$19.85M–
FY2015Dec 31, 2015-$18.65M–
FY2014Dec 31, 2014-$1.26M–
FY2013Dec 31, 2013-$3.48M-107.7%
FY2012Dec 31, 2012$45.05M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$95.67M–
Q1 FY2026Mar 31, 2026-$89.03M–
Q4 FY2025Dec 31, 2025-$81.80M–
Q3 FY2025Sep 30, 2025-$72.03M–
Q2 FY2025Jun 30, 2025-$64.39M–
Q1 FY2025Mar 31, 2025-$61.70M–
Q4 FY2024Dec 31, 2024-$55.17M–
Q3 FY2024Sep 30, 2024-$50.26M–
Q2 FY2024Jun 30, 2024-$32.67M–
Q1 FY2024Mar 31, 2024-$46.38M–
Q4 FY2023Dec 31, 2023-$35.48M–
Q3 FY2023Sep 30, 2023-$49.28M–
Q2 FY2023Jun 30, 2023-$35.35M–
Q1 FY2023Mar 31, 2023-$36.62M–
Q4 FY2022Dec 31, 2022-$37.08M–
Q3 FY2022Sep 30, 2022-$30.79M–
Q2 FY2022Jun 30, 2022-$17.41M–
Q1 FY2022Mar 31, 2022-$18.64M–
Q4 FY2021Dec 31, 2021-$21.22M–
Q3 FY2021Sep 30, 2021-$15.23M–
Q2 FY2021Jun 30, 2021-$13.99M–
Q1 FY2021Mar 31, 2021-$21.11M–
Q4 FY2020Dec 31, 2020-$13.94M-172.6%
Q3 FY2020Sep 30, 2020-$11.95M–
Q2 FY2020Jun 30, 2020-$11.16M–
Q1 FY2020Mar 31, 2020-$13.71M–
Q4 FY2019Dec 31, 2019$19.19M–
Q3 FY2019Sep 30, 2019-$7.10M–
Q2 FY2019Jun 30, 2019-$9.01M–
Q1 FY2019Mar 31, 2019-$9.03M–
Q4 FY2018Dec 31, 2018-$7.41M–
Q3 FY2018Sep 30, 2018-$13.74M–
Q2 FY2018Jun 30, 2018-$5.68M–
Q1 FY2018Mar 31, 2018-$8.40M–
Q4 FY2017Dec 31, 2017-$6.90M–
Q3 FY2017Sep 30, 2017-$8.64M–
Q2 FY2017Jun 30, 2017-$6.90M–
Q1 FY2017Mar 31, 2017-$6.60M–
Q4 FY2016Dec 31, 2016-$4.70M–
Q3 FY2016Sep 30, 2016-$4.57M–

More Xenon Pharmaceuticals figures

See a number that looks wrong?